



EUDRACT # 2016-002181-32
RESULTS POSTING PLACEHOLDER
October 24, 2022

**A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety,
Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of
Weekly RG-012 Injections in Patients with Alport Syndrome**

This statement is in compliance with the Commission Guideline: Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006 (2012/C 302/03) on results posting and as requested in the Joint Letter by the European Commission, EMA and HMA regarding the requirements to provide results for authorised clinical trials in EUDRACT.

Please be advised that the above-mentioned clinical trial was terminated without any enrollment; therefore, no results exist for posting.